menu-hamburger-svgrepo-com

WEBINAR REPLAY

Cervical cancer prevention with Cervarix

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Presented by

:
:
DAYS
HRS
MINS

BOOKINGS

Vector featuring three healthcare professionals treating cervical cancer

Key points from the webinar include:

Persistent HPV infection:

  • The transition from persistent HPV infection to invasive carcinoma can take several years.
  • There are over 130 HPV subtypes, with 15 classified as oncogenic. HPV-16 and HPV-18 are the most common, accounting for >70% of invasive CxCa cases.

 

Cervarix targets HPV types 16 and 18:

  • Cervarix is a bivalent vaccine containing viral-like particles (VLPs) of HPV 16 and 18.
  • It provides protection against pre-cancerous cervical lesions associated with non-vaccine oncogenic HPV types like HPV-31 and HPV-45.

 

Importance of sustained protection:

  • Cervarix contains an adjuvant system with aluminium hydroxide and monophosphoryl lipid A (a toll-like receptor 4 agonist). Adjuvanted formulations show a high and sustained immune response over time, while non-adjuvanted ones elicit a weaker and quickly waning response. Immunostimulants further boost the overall efficacy.
  • Clinical studies, including Efficacy Study of HPV-16/​18 Vaccine (GSK 580299) to Prevent HPV-16 and/​or -18 Cervical Infection in Young Healthy Women (HPV-001), demonstrate strong and sustained immune responses in young girls over ten years.
  • Mathematical models project that adjuvanted Cervarix can offer sustained protection for >50 years.
  • Follow-up studies, such as the Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults (HPV 007) and the Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil (HPV 023), affirm Cervarix’ s sustained protection >10 years and indicate potential protection for >50 years.
  • Cervarix consistently demonstrates efficacy against various stages, including persistent infection and cervical intraepithelial neoplasia.

 

Real-world evidence:

  • Evidence from the United Kingdom, Scotland, and South Africa highlights substantial reductions in CxCa and high-grade lesions, emphasising the vaccine's impact and potential economic benefits.
  • Safety analyses in males show a comparable safety profile to the hepatitis B vaccine, with continuous monitoring for emerging risks.

 

Conclusion

Cervarix, through its carefully formulated adjuvanted system, has demonstrated efficacy in providing sustained protection against HPV-related diseases, particularly CxCa. Real-world evidence supports its positive impact on reducing disease burden and healthcare resource utilisation.

To watch a replay of the video, click here: https://vimeo.com/event/4077869

Sign in to access full articles and earn your CPD points.

Clinical and CPD content is compiled by Key Opinion Leaders and our expert medical editors.

Already registered? Login here

Past webinars

Suggested clinical & CPD content

CPD: Activitypt

Related articles

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Please check your email for an activation mail. Click the activation link to activate your account

Stay up to date

Search for anything across CPD, webinars and journals
idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! You have successfully booked your seat.

All webinar details will be emailed to your email address.

Did you know, you can book future webinars with a single click if you register an account with Medical Academic.

Congratulations! Your account was successfully created.

Your webinar seat has been booked and all webinar details will be emailed to your registered email address

Why not register for Medical Academic while booking your seat for this webinar?

Future Medical Academic webinars can be booked with a single click, all with a Medical Academic account… and it’s FREE.

Book webinar & create your account

* (Required)

idea

1000’s of Clinical and CPD content compiled by Key Opinion Leaders and our expert medical editors.

connection

Access to medical webinars and events

Group 193

Access medical journals from industry leaders and expert medical editorials.

Congratulations! Your account was successfully created.

Thank you for registering. You can now log in to your account.

Create your account

* (Required)

Login with One Time Pin (OTP)

Enter your registered email address to receive an OTP

A verification code will be sent to your email address. Please ensure that admin@medicalacademic.co.za is on your safe sender list.

We've sent your OTP
Welcome to Medical Academic​

Get the most out of Medical Academic by telling us your occupation. This helps us create more great content for you and the community.